...
首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Suspected periprosthetic joint infection after total knee arthroplasty under propofol versus sevoflurane anesthesia: a retrospective cohort study
【24h】

Suspected periprosthetic joint infection after total knee arthroplasty under propofol versus sevoflurane anesthesia: a retrospective cohort study

机译:疑似膝关节关节置换术后蛇形关节型接头感染与七氟醚麻醉,回顾性队列研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose Periprosthetic joint infection is a serious complication of total knee arthroplasty. Though there are many factors that might increase its risk, the use of propofol for maintaining general anesthesia could theoretically increase the incidence of infection because of its lipid component that supports bacterial growth. Nevertheless, the relationship between anesthetic maintenance agents and the occurrence of periprosthetic joint infection remains uncertain. The purpose of this study was to compare the incidence of suspected early-onset periprosthetic joint infection between patients undergoing total knee arthroplasty under propofol vs sevoflurane anesthesia. Methods We conducted a retrospective cohort study of patients in the national inpatient Diagnosis Procedure Combination database in Japan who underwent total knee arthroplasty. Suspected periprosthetic joint infection was surrogately defined as the need for arthrocentesis or debridement within 30 days of surgery. Propensity score matching was performed between patients who received either propofol or sevoflurane for anesthetic maintenance to determine the proportion of those with infection. Results Eligible patients ( n = 21,899) were categorized into either the propofol ( n = 7,439) or sevoflurane ( n = 14,460) groups. In the 5,140 propensity-matched patient pairs, there was no significant difference in the proportion of arthrocentesis or debridement [1.3% propofol vs 1.7% sevoflurane; respectively (relative risk, 0.76; 95% CI, 0.55 to 1.04; P = 0.10)] between the groups. The mean (SD) length of stay in the propofol group was significantly longer than in the sevoflurane group [32.5 (18.4) days vs 31.4 (14.4) days, respectively; mean difference, 1.1; 95% CI, 0.5 to 1.8; P < 0.001]. Conclusion Propensity score analysis suggested no significant association between the choice of anesthetic maintenance agent and the occurrence of suspected early-onset periprosthetic joint infection in patients undergoing total knee arthroplasty.
机译:目的的垂直关节感染是全膝关节形成术的严重并发症。虽然有许多可能会增加其风险的因素,但是对于维持全身麻醉的异丙酚的使用可能理论上可以增加感染的发生率,因为其脂质组分支持细菌生长。尽管如此,麻醉维持剂与围页刺激性关节感染的发生仍然不确定。本研究的目的是比较在异丙酚与七氟醚麻醉下进行全膝关节置换术患者之间怀疑早期发病率关节感染的发病率。方法我们对日本全国住院治疗程序组合数据库进行了回顾性队列研究,膝关节形成术。疑似宫骨粒细胞接触感染因在手术后30天内被替代地定义为关节周期度或清创。在接受异丙酚或七氟醚的患者之间进行倾向得分匹配,用于麻醉维持,以确定感染者的比例。结果符合条件的患者(n = 21,899)分为异丙酚(n = 7,439)或七氟醚(n = 14,460)组。在5,140型匹配的患者对中,关节整营术或清除的比例没有显着差异[1.3%的异丙酚Vs 1.7%七氟醚;分别(相对风险,0.76; 95%CI,0.55至1.04; p = 0.10)]。丙砜基团的平均值(SD)保持率明显长于七氟醚基[32.5(18.4)天与31.4天(14.4)天;平均差异,1.1; 95%CI,0.5至1.8; p <0.001]。结论倾向评分分析表明,在经过全膝关节置换术患者中,麻醉维持剂的选择与疑似早期发作关节感染的缺陷之间没有显着关联。

著录项

  • 来源
  • 作者单位

    Department of Public Health Health Management and Policy Nara Medical University;

    Department of Clinical Epidemiology and Health Economics School of Public Health Graduate School;

    Department of Anesthesiology Nara Medical University;

    Department of Public Health Health Management and Policy Nara Medical University;

    Department of Public Health Health Management and Policy Nara Medical University;

    Department of Artificial Joint and Regenerative Medicine for Bone and Cartilage Nara Medical;

    Department of Clinical Epidemiology and Health Economics School of Public Health Graduate School;

    Department of Clinical Epidemiology and Health Economics School of Public Health Graduate School;

    Department of Anesthesiology Nara Medical University;

    Department of Public Health Health Management and Policy Nara Medical University;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 麻醉学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号